SELLAS Life Sciences Group (SLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $4.00 price target.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Jason McCarthy has given his Buy rating due to a combination of factors, primarily focusing on the promising upcoming catalysts for SELLAS Life Sciences Group. The company is well-funded, having ended the first quarter of 2025 with $28.4 million in cash and an additional $4 million raised through warrant exercises, which should support them through key events in 2025.
A significant factor in the Buy rating is the anticipated release of top-line data from the Phase 3 trial of Galinpepimut-S (GPS) in acute myeloid leukemia (AML) expected mid-year. This follows a positive interim analysis that showed promising survival rates compared to historical benchmarks. Additionally, the ongoing Phase 2a trial of SLS009 in combination with other therapies has shown encouraging safety and efficacy results, with median overall survival rates exceeding historical data. These developments, coupled with a strategic valuation model that includes potential commercialization and risk adjustments, underpin the optimistic outlook for the company’s stock.
In another report released yesterday, Alliance Global Partners also reiterated a Buy rating on the stock with a $7.50 price target.